Drug Trial Radar · NCT07141030
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Apr 11, 2025
Primary completion
Oct 20, 2025
Study completion Oct 20, 2025
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study adopts a multicenter, single-dose, open-label, and parallel design, which is aimed at assessing the PK and safety profiles of GZR18 Injection in subjects with normal renal function and those with mild, moderate or severe renal impairment. The study duration for each subject in this study is up to 50 days, including a screening period of up to 14 days (Day-14 to Day-1), an 8-day dosing/observation period (Day 1 to Day 8), and a 28-day follow-up period (Day 9 to Day 36).
Conditions
- Obesity/Overweight
Interventions
GZR18 injectionDrug
GZR18 injection:3mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax:Maximum plasma concentrationTime frame: through study completion, an average of 36 days
- AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.Time frame: through study completion, an average of 36 days
- AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose.Time frame: through study completion, an average of 36 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.